Background:

KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway.Target: KIN1408 activate IRF3 through MAVS, thereby inhibiting infection by viruses of the families Flaviviridae (West Nile virus, dengue virus and hepatitis C virus), Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (respiratory syncytial virus, Nipah virus) .

[1]. Green RR, et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. Genom Data. 2016 Feb 1;7:290-2.